4D Molecular Therapeutics Inc
FDMT
M
|
$25.29
2.06%
2.02%
630K
|
Health Technology
(0.0% 1d) (-25.4% 1m) (25.8% 1y) (0.0% 2d) (-1.2% 3d) (-4.8% 7d) (-100.0% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 1,293,772,467
https://www.4dmoleculartherapeutics.com
Sec Filling | Patents | 83 employees
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
urea ceiling education antibody gene therapies t-cell
add to watch list Paper trade email alert is off
Press-releases
Form Bio Establishes Scientific Advisory Board, Comprised of Renowned Experts in Cell and Gene Therapy, for Advancing AI-Driven Therapies
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: -1.23%
H: 0.0%
C: 0.0%
cell for
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: -4.77%
H: 0.11%
C: -6.73%
update treatment fibrosis
4DMT to Participate in Upcoming Investor Conferences
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 0.99%
H: 1.01%
C: -3.1%
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 2.68%
H: 3.96%
C: 2.09%
year financial results
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
Published: 2024-02-12 (Crawled : 13:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 0.24%
H: 2.16%
C: -2.96%
disease trials
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Published: 2024-02-07 (Crawled : 05:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 0.42%
H: 1.35%
C: -15.32%
offering therapeutics molecular
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - February 07, 2024
Published: 2024-02-07 (Crawled : 12:00) - biospace.com/
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 0.42%
H: 1.35%
C: -15.32%
offering therapeutics molecular
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
Published: 2024-02-05 (Crawled : 21:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 2.11%
H: 1.27%
C: 0.73%
offering therapeutics molecular
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
Published: 2024-02-03 (Crawled : 00:20) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
| Email alert
Add to watchlist
prism favorable positive trial
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 2.46%
H: 1.28%
C: 0.5%
disease prism treatment trial
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10